| 2017-12-08 17:20:19|
AKTX, UTSI… 17:20 12/08 12/08/17
On The Fly: After Hours Movers
HIGHER: Akari Therapeutics (AKTX), up 14.3% after it said that its Coversin Phase II trial met its primary endpoint... UTStarcom (UTSI), up 7.6% after the Tonghao Group reported a 9.9% stake in the company... Fate Therapeutics (FATE), up 6.7% after it treated its first patient in the APOLLO study of Fate-NK100... Overstock.com (OSTK), up 3.8% after Morgan Stanley (MS) reported an 11.4% passive stake in the company. LOWER: Cytokinetics (CYTK), down 5% after it said its VITALITY-ALS trial did not meet its primary endpoint.
See Street Research during your Free Trial